Detalhe da pesquisa
1.
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
Nature
; 623(7989): 1034-1043, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993715
2.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272527
3.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194692
4.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
5.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet
; 402(10402): 641-654, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295445
6.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Blood
; 139(12): 1794-1806, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699592
7.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Haematologica
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38618681
8.
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
Eur Heart J
; 44(22): 2029-2042, 2023 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36939851
9.
Infectious complications of car T-cell therapy: A longitudinal risk model.
Transpl Infect Dis
; 25 Suppl 1: e14148, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37695203
10.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol
; 23(8): 1066-1077, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839786
11.
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
Br J Haematol
; 195(5): 757-763, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34581433
12.
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 26(5): 1025-1027, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32018063
13.
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Biol Blood Marrow Transplant
; 26(7): 1239-1246, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32298807
14.
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
Br J Haematol
; 2024 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38797526
15.
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.
Am J Hematol
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38769663
16.
Double hit and double expressors in lymphoma: Definition and treatment.
Cancer
; 124(24): 4622-4632, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30252929
17.
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Blood
; 137(24): 3454-3459, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881502
18.
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Haematologica
; 105(8): e404-e407, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753931
19.
Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.
Target Oncol
; 2024 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38896212
20.
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Clin Lymphoma Myeloma Leuk
; 24(2): 83-93, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827881